While people linger on ventilators or die, the FDA wants more data.

Why not issue and announce Conditional Approval of Leronlimab while continuing to collect data via the Trials? If it turns out the great results are not related to Leronlimab, revoke the Approval. In the meantime, thousands of lives could be saved.